
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Explore how next-gen QMS delivers digital transformation by seamlessly connecting enterprise-wide systems, processes,, documentation, and data in a cost-effective manner






